Xeris Biopharma (XERS) Insider Trading & Ownership $3.49 +0.08 (+2.35%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Xeris Biopharma (NASDAQ:XERS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.56%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$19,875.45Number OfInsiders Selling(Last 12 Months)0 Get XERS Insider Trade Alerts Want to know when executives and insiders are buying or selling Xeris Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address XERS Insider Buying and Selling by Quarter Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Xeris Biopharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/9/2024John P SchmidDirectorBuy4,285$2.37$10,155.45 3/14/2024John P SchmidDirectorBuy4,500$2.16$9,720.00 (Data available from 1/1/2013 forward) XERS Insider Trading Activity - Frequently Asked Questions Who is on Xeris Biopharma's Insider Roster? The list of insiders at Xeris Biopharma includes Jeffrey W Sherman, John P Schmid, John Patrick Shannon Jr, Paul R Edick, and Steven Prestrelski. Learn more on insiders at XERS. What percentage of Xeris Biopharma stock is owned by insiders? 4.56% of Xeris Biopharma stock is owned by insiders. Learn more on XERS's insider holdings. Which Xeris Biopharma insiders have been buying company stock? The following insiders have purchased XERS shares in the last 24 months: Jeffrey W Sherman ($10,098.00), John P Schmid ($29,690.45), John Patrick Shannon Jr ($50,461.16), and Paul R Edick ($23,800.00). How much insider buying is happening at Xeris Biopharma? Insiders have purchased a total of 61,454 XERS shares in the last 24 months for a total of $114,049.61 bought. Xeris Biopharma Key ExecutivesMr. Paul R. Edick (Age 68)Chairman & CEO Compensation: $1.21MMr. John P. Shannon (Age 62)President & COO Compensation: $918.15kMr. Steven M. Pieper (Age 46)Chief Financial Officer Compensation: $681.14kMs. Beth P. Hecht J.D. (Age 60)Chief Legal Officer & Corporate Secretary Compensation: $695.44kDr. Kenneth E. Johnson Pharm. D. (Age 61)Pharm.D., Senior VP of Global Development & Medical Affairs Compensation: $596.97kMs. Allison WeySenior Vice President of Investor Relations & Corporate CommunicationsMr. Kevin McCullochChief Commercial Officer More Insider Trading Tools from MarketBeat Related Companies Akero Therapeutics Insider Transactions Tarsus Pharmaceuticals Insider Transactions Amphastar Pharmaceuticals Insider Transactions Disc Medicine Insider Transactions CG Oncology Insider Transactions Harmony Biosciences Insider Transactions Xencor Insider Transactions Arcutis Biotherapeutics Insider Transactions Nurix Therapeutics Insider Transactions Arcus Biosciences Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:XERS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
